Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.
The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.
The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.
Of the 29 companies in the index, 16 firms' share prices retreated while the other 13 saw their stock prices rise month over month.
The German diagnostics firm recently signed an agreement to be acquired by US-based OpGen in a transaction that is slated to close in early 2020.
The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected.
The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.
Of the 27 companies in the index, 14 firms' stocks were down, while 13 companies' share prices increased.
For the six-month period ended June 30, the molecular diagnostic company's revenues fell to $10.9 million from $17.2 million in H1 2018.
The firm moved closer to commercializing its lung transplant test, and it was notified by New York State that it could begin testing patient samples using its DTC celiac disease test.